##  [Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS](/us-en/news/media-releases/phase-iii-data-lancet-show-novartis-siponimod-significantly-improved-outcomes-patients-secondary-progressive-ms-0 "Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS") 

  Mar 22, 2018